(Q35855740)

10 August 2017

title

Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea (English)

1 reference

10 August 2017

0 references

irritable bowel syndrome

1 reference

M Pimentel

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 January 2016

1 reference

Alimentary Pharmacology & Therapeutics

10 August 2017

published in

1 reference

10 August 2017

volume

43 Suppl 1

1 reference

10 August 2017

page(s)

37-49

1 reference

GP perspectives of irritable bowel syndrome--an accepted illness, but management deviates from guidelines: a qualitative study

10 August 2017

cites work

1 reference

American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation

21 January 2018

1 reference

Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study.

21 January 2018

1 reference

Costs of irritable bowel syndrome in the UK and US.

21 January 2018

1 reference

Alterations in the intestinal microbiota and functional bowel symptoms

21 January 2018

1 reference

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months

21 January 2018

1 reference

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

Rifaximin--a novel antimicrobial for enteric infections

21 January 2018

1 reference

Bile acids improve the antimicrobial effect of rifaximin

21 January 2018

1 reference

Pharmacotherapy for hepatic encephalopathy

21 January 2018

1 reference

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

21 January 2018

1 reference

In vitro activity and fecal concentration of rifaximin after oral administration

21 January 2018

1 reference

In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth.

21 January 2018

1 reference

Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations

21 January 2018

1 reference

Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections

21 January 2018

1 reference

Rifaximin: in vitro and in vivo antibacterial activity--a review

21 January 2018

1 reference

Rifaximin treatment in hepatic encephalopathy

21 January 2018

1 reference

Antibiotic treatment of constipation-predominant irritable bowel syndrome.

21 January 2018

1 reference

The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome

21 January 2018

1 reference

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome.

21 January 2018

1 reference

A systematic review of diagnostic tests for small intestinal bacterial overgrowth

21 January 2018

1 reference

Evaluating a bacterial hypothesis in IBS using a modification of Koch's postulates: part 1.

21 January 2018

1 reference

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients

21 January 2018

1 reference

Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

Evaluation of harm in the pharmacotherapy of irritable bowel syndrome

21 January 2018

1 reference

In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008

21 January 2018

1 reference

Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.

21 January 2018

1 reference

Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?

21 January 2018

1 reference

Immune activation in patients with irritable bowel syndrome

21 January 2018

1 reference

Rifaximin in the treatment of inflammatory bowel disease

21 January 2018

1 reference

Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation

21 January 2018

1 reference

Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy

21 January 2018

1 reference

Pregnane X receptor as a target for treatment of inflammatory bowel disorders

21 January 2018

1 reference

Rifaximin: beyond the traditional antibiotic activity

21 January 2018

1 reference

Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.

21 January 2018

1 reference

Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles

21 January 2018

1 reference

Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome

21 January 2018

1 reference

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.13437

1 reference

10 August 2017

1 reference